Avrobio Inc (AVRO) Receives a Buy from H.C. Wainwright

By Ryan Adsit

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Avrobio Inc (NASDAQ: AVRO), with a price target of $40. The company’s shares closed yesterday at $25.13, close to its 52-week low of $21.58.

According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.1% and a 42.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avrobio Inc with a $39.50 average price target, implying a 57.2% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.


See today’s analyst top recommended stocks >>

The company has a one-year high of $53.70 and a one-year low of $21.58. Currently, Avrobio Inc has an average volume of 140.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. is a clinical stage company that engages in the development of disruptive therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. The company was founded by Jeffrey Medin and Christopher Paige in 2015 and is headquartered in Cambridge, MA.